Europe - Euronext Milan - BIT:1FME - DE0005785802 - Common Stock
The current stock price of 1FME.MI is 40.4 EUR.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| FRE.DE | FRESENIUS SE & CO KGAA | 14.36 | 27.59B | ||
| FME.DE | FRESENIUS MEDICAL CARE AG | 10.84 | 23.92B | ||
| HI.MI | HEALTH ITALIA SPA | 18.26 | 56.24M | ||
| V3V.DE | FAMICORD AG | N/A | 105.84M |
Fresenius Medical Care AG engages in the provision of products and services for individuals with renal diseases. The company is headquartered in Bad Homburg Vor Der Hohe, Hessen and currently employs 109,916 full-time employees. The firm provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD) and offers other extracorporeal therapies, as well as other healthcare services. The company has two operating segments such as care delivery segment which consolidates the global health care services business and care enablement segment includes research and development (R&D), manufacturing, supply chain, and commercial operations. The company develops and manufactures health care products, which includes dialysis and non-dialysis products. Such as hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. The company owns, operates, or manages dialysis clinics sells products to other dialysis providers.
FRESENIUS MEDICAL CARE AG
Else-Kroener-Strasse 1
Bad Homburg vor der Hohe HESSEN DE
Employees: 111513
Phone: 4961726090
Fresenius Medical Care AG engages in the provision of products and services for individuals with renal diseases. The company is headquartered in Bad Homburg Vor Der Hohe, Hessen and currently employs 109,916 full-time employees. The firm provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD) and offers other extracorporeal therapies, as well as other healthcare services. The company has two operating segments such as care delivery segment which consolidates the global health care services business and care enablement segment includes research and development (R&D), manufacturing, supply chain, and commercial operations. The company develops and manufactures health care products, which includes dialysis and non-dialysis products. Such as hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. The company owns, operates, or manages dialysis clinics sells products to other dialysis providers.
The current stock price of 1FME.MI is 40.4 EUR. The price decreased by -3.56% in the last trading session.
FRESENIUS MEDICAL CARE AG (1FME.MI) has a dividend yield of 3.54%. The yearly dividend amount is currently 1.19.
1FME.MI has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
The PE ratio for FRESENIUS MEDICAL CARE AG (1FME.MI) is 10.74. This is based on the reported non-GAAP earnings per share of 3.76 and the current share price of 40.4 EUR.
FRESENIUS MEDICAL CARE AG (1FME.MI) currently has 111513 employees.
FRESENIUS MEDICAL CARE AG (1FME.MI) has a market capitalization of 23.71B EUR. This makes 1FME.MI a Large Cap stock.
ChartMill assigns a technical rating of 3 / 10 to 1FME.MI.
ChartMill assigns a fundamental rating of 5 / 10 to 1FME.MI. Both the profitability and the financial health of 1FME.MI get a neutral evaluation. Nothing too spectacular is happening here.
Over the last trailing twelve months 1FME.MI reported a non-GAAP Earnings per Share(EPS) of 3.76. The EPS increased by 16.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 3.66% | ||
| ROA | 2.33% | ||
| ROE | 5.55% | ||
| Debt/Equity | 0.73 |
29 analysts have analysed 1FME.MI and the average price target is 47.84 EUR. This implies a price increase of 18.41% is expected in the next year compared to the current price of 40.4.
For the next year, analysts expect an EPS growth of 21.73% and a revenue growth 1.57% for 1FME.MI